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The viability of vertebrate cells depends on a complex
signaling interplay between survival factors and cell-
death effectors. Subtle changes in the equilibrium be-
tween these regulators can result in abnormal cell
proliferation or cell death, leading to various patho-
logical manifestations [1, 2]. Death-associated protein
kinase (DAPK) is a multidomain calcium/calmodulin
(CaM)-dependent Ser/Thr protein kinase with an im-
portant role in apoptosis regulation and tumor sup-
pression [3–6]. The molecular signaling mechanisms
regulating this kinase, however, remain unclear. Here,
we show that DAPK is phosphorylated upon activa-
tion of the Ras-extracellular signal-regulated kinase
(ERK) pathway [7]. This correlates with the suppres-
sion of the apoptotic activity of DAPK. We demon-
strate that DAPK is a novel target of p90 ribosomal
S6 kinases (RSK) 1 and 2, downstream effectors of
ERK1/2 [8–11]. Using mass spectrometry, we iden-
tified Ser-289 as a novel phosphorylation site in
DAPK, which is regulated by RSK. Mutation of Ser-
289 to alanine results in a DAPK mutant with en-
hanced apoptotic activity, whereas the phosphomi-
metic mutation (Ser289Glu) attenuates its apoptotic
activity. Our results suggest that RSK-mediated phos-
phorylation of DAPK is a unique mechanism for sup-
pressing the proapoptotic function of this death ki-
nase in healthy cells as well as Ras/Raf-transformed
cells.
Results and Discussion
In HEK293E cells, overexpression of DAPK results in
extensive apoptotic cell death by 24 hr posttransfection
(Figure 1A, compare bar 1 to bar 5). We sought to deter-
mine whether activation of cell-survival pathways in
DAPK-expressing cells would provide protection against
cell death [7, 12]. The Ras-MAPK (mitogen-activated
protein kinase) pathway has been shown to promote
cell-survival signaling and is the major mechanism for
protection against cell death in certain cell types [7].
Interestingly, we found that treatment of cells with the
phorbol ester PMA, which activates the Ras-MAPK
pathway but not the PI3K-Akt/PKB pathway, antago-
nized the death-inducing activity of DAPK, leading to
increased survival of DAPK-expressing cells (Figure
1A). In contrast, when cells were pretreated with the
MEK1/2/5 inhibitor U0126, there was enhanced cell*Correspondence: john_blenis@hms.harvard.edudeath and PMA did not attenuate the apoptotic effects
of DAPK (Figure 1A). We considered the possibility that
DAPK was inhibited upon phosphorylation by kinases
downstream of MEK in this cascade. Because RSK is
a potential cell-survival kinase in this cascade [7], we
used an antibody that recognizes the consensus phos-
phorylation motif, RXRXXpS/T, which recognizes sub-
strates of several basophilic kinases within the AGC
family such as RSK, as well as Akt and ribosomal S6
kinase 1 (S6K1) [13–15]. Using this antibody, we found
that PMA stimulated basophilic site phosphorylation of
endogenous (see Figure S1A in the Supplemental Data
available with this article online) and overexpressed
DAPK (Figure 1B). Importantly, we also found that phos-
phorylation of DAPK, similar to the death-protecting ef-
fect of PMA, was completely inhibited by U0126. These
results indicated that activation of the Ras-MAPK cas-
cade induced MEK-dependent phosphorylation of DAPK,
suggesting that this cascade may inhibit apoptosis by
directly regulating DAPK phosphorylation.
To further characterize the pathways leading to
DAPK phosphorylation, we stimulated cells with dif-
ferent agonists and analyzed them for DAPK phosphor-
ylation. Stimulation of cells with either PMA or EGF led
to robust activation of the ERK-MAPK pathway and
DAPK phosphorylation, whereas incubation of cells
with insulin, a PI3-kinase agonist, or with anisomycin, a
p38-MAPK agonist, did not alter DAPK phosphorylation
(Figure 1C). Consistent with these results, PMA-induced
phosphorylation of DAPK was completely inhibited by
U0126 and BIM (bisindolylmaleimide I), indicating that
PMA-stimulated DAPK phosphorylation requires MEK
and protein kinase C (PKC), respectively. Furthermore,
treatment of cells with wortmannin or rapamycin did
not alter DAPK phosphorylation, again demonstrat-
ing that the PI3-kinase and mTOR pathways are not
necessary for these effects (Figure S1B). These data
suggests that basophilic kinases regulated by the Ras-
MAPK pathway are likely involved in DAPK phosphory-
lation stimulated by PMA and exclude the involvement
of other basophilic kinases including Akt, MSK, and
S6K.
To further establish the link between Ras signaling
and DAPK phosphorylation, we transfected activated
versions of Ras (Ras61L), B-Raf (ER-B-Raf), and MEK
(MEK-DD) in cells overexpressing DAPK [16, 17]. These
oncogenic signaling proteins potently stimulated
growth-factor- and phorbol-ester-independent phos-
phorylation of DAPK (Figures 1D and 1E), suggesting
that activation of the Ras-MAPK pathway is sufficient
to induce DAPK phosphorylation. Finally, we also ob-
served a reduction in DAPK phosphorylation by PMA
by partially knocking down endogenous ERK1/2 (Fig-
ure S1C).
The Ras-MAPK pathway activates the RSK family of
proteins in response to growth factors and phorbol es-
ters [8]. Activation of RSK coincides with oncogenic
transformation [18], stimulation of G0/G1 transition [19–
21], and differentiation of PC12 cells [10]. To determine
whether RSK could directly phosphorylate DAPK, we
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1763Figure 1. Inhibition of Cell Death and Phosphorylation of DAPK by the Activation of Ras-MAPK Pathway
(A) HEK293E cells were transfected with either the vector or Flag-DAPK construct, along with EGFP plasmid (10:1 ratio), serum-starved 10 hr
after transfection, and treated with DMSO alone or PMA (50 ng/ml) with or without U0126 (10 M) or UO126 alone. After 24 hr, cells were
fixed and stained with activated anti-caspase-3 antibody. To determine the percent of apoptotic cells, we scored 100 GFP-positive cells in
six different fields for apoptotis by counting cells positive for caspase-3 staining. All experiments were repeated at least three times, and the
results are represented as means ± standard error.
(B) HEK293E cells, transfected with either the vector or Flag-DAPK, were serum-starved for 18 hr and then stimulated with 50 ng/ml PMA for
further 15 min, either alone or after pretreatment of cells with U0126 (10 M) for 30 min. The lysates were immunoprecipitated with anti-FLAG
antibody, and DAPK phosphorylation on RXRXXS/T motif was analyzed after immunoblotting with Akt-pSub antibody [α-(P)DAPK]. The cell
lysates were also immunoblotted for total protein levels (α-FLAG) and ERK1/2 phosphorylation.
(C) DAPK-transfected cells were serum-starved and stimulated with either 50 ng/ml PMA (15 min), 50 ng/ml EGF (15 min), 100 nM insulin (30
min), or 2 M anisomycin (30 min). DAPK was immunoprecipitated from the cell lysates and immunoblotted as in (B), for DAPK phosphoryla-
tion, total DAPK levels (α-FLAG), Akt phosphorylation [α-(P)Akt (S473)], (P)-p38, and ERK1/2.
(D) HEK293E cells were transfected with DAPK and cotransfected with vector, MEK-DD, or activated Ras (Ras61L). The vector-cotransfected
cells were stimulated with PMA (50 ng/ml) for 15 min, after pretreatment of cells with 10 M U0126 (30 min), where indicated. Cell extracts
were immunoprecipitated and immunoblotted as in (C).
(E) NIH3T3 fibroblasts expressing a conditionally active form of B-Raf were transfected with DAPK. Cells were serum-starved for 18 hr and
left untreated or treated with 1 M 4-hydroxy tamoxifen (4-HT) for the indicated time periods for the induction of B-Raf [16]. Cells were
immunoprecipitated and immunoblotted as in (C).performed an in vitro kinase assay with immunoprecipi-
tated DAPK as substrate. The kinase-inactive DAPK
(K42A) was used in this experiment to avoid potential
32P incorporation through possible DAPK autophosphor-
ylation. DAPK was phosphorylated in vitro by activated
RSK1 but not by kinase-inactive RSK1, and RSK-depen-
dent DAPK phosphorylation was inhibited by UO126
(Figure 2A). To test whether RSK can phosphorylate
DAPK in vivo, we coexpressed RSK1 with DAPK in
HEK293E cells, which resulted in an 8-fold increase in
phosphorylation of DAPK upon stimulation with PMA
(Figure 2B). Moreover, when coexpressed in cells, ki-
nase-inactive RSK1 did not increase DAPK phosphory-lation (Figure 2B), suggesting that RSK kinase activity
is necessary for phosphorylation of DAPK in cells.
There was no effect on DAPK phosphorylation when
cells were coexpressed with either Akt or MSK2 (Figure
S2A). We also observed that both RSK1 and RSK2 were
able to phosphorylate DAPK in HEK293E cells (Figure
S2B). Interestingly, a constitutively active form of RSK1
(myrRSK1) [8, 22], when coexpressed with DAPK,
strongly induced DAPK phosphorylation (Figure 2C).
RSK has been shown to be associated with most of
its physiological targets [8]. In the present study, we
also observed a stimulation-independent interaction of
RSK1 with DAPK (Figure 2D).
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1764Figure 2. RSK Interacts with and Phosphorylates DAPK In Vitro and In Vivo
(A) HEK293E cells were transfected with either HA-RSK1 or kinase-inactive RSK1 (RSK1/), serum-starved for 18 hr, and treated with PMA
(50 ng/ml) for 15 min, with or without pretreatment of cells with U0126 (10 M) for 30 min, and immunoprecipitated with α-HA antibodies.
Kinase-inactive DAPK (K42A)-expressing cells were separately lysed, and DAPK was immunoprecipitated with α-FLAG antibodies. These
immunoprecipitates were incubated with RSK immunoprecipitates in a kinase reaction containing [γ-32P] ATP for 10 min. The samples were
subjected to SDS-PAGE, and the gel was autoradiographed. The lysates were immunoblotted for protein levels, RSK expression, and ERK1/2.
(B) Cells were transfected with DAPK and cotransfected with either wild-type RSK1 or the kinase-inactive RSK1 (RSK1/). After serum
starvation for 18 hr, cells were treated with PMA (50 ng/ml) for 15 min and lysed. DAPK was immunoprecipitated and immunoblotted for
phosphorylation on RXRXXS/T motifs [(P)DAPK]. Lysates were immunoblotted for levels of transfected proteins and ERK1/2.
(C) HEK293E cells were transfected with DAPK and cotransfected with either wild-type RSK1 or myristoylated RSK1. Cells were serum-
starved, stimulated, immunoprecipitated, and immunoblotted as in (B).
(D) HEK293E cells were transfected with Flag-DAPK and cotransfected with HA-RSK1. Cells were serum-starved for 18 hr followed by
stimulation with PMA (50 ng/ml) for 15 min. The lysates were immunoprecipitated with α-Flag antibody and immunoblotted for DAPK phos-
phorylation. The coimmunoprecipitated RSK was immunoblotted with α-HA antibody. The lysates were also immunoblotted for total protein
levels, RSK expression, and ERK1/2.
(E) HEK293 cells were transfected with either the mock or RSK1/2 siRNA and cotransfected with Flag-DAPK. Cells were starved, stimulated,
immunoprecipitated, and immunoblotted as in (D).To further validate the role of RSK1/2 in DAPK phos-
phorylation, we eliminated RSK1/2 expression by par-
tially knocking down endogenous RSK1/2 with siRNA.
This resulted in a dramatic decrease in DAPK phos-
phorylation (Figure 2E), indicating that both RSK1 and
RSK2 play a role in regulating DAPK phosphorylation.
Taken together, these results demonstrate that DAPK is
a specific target of RSK.
To identify potential RSK phosphorylation sites in
DAPK, tryptic peptides of immunopurified DAPK were
subjected to LC-MS/MS/MS analysis with a Fourier
transform ion cyclotron resonance (FTICR)/ion trap hy-
brid mass spectrometer (Figure 3A). One tryptic phos-
phopeptide, found uniquely from PMA-treated cells,
showed phosphorylation at Ser-289, a residue lying in
a minimal target site for RSK. The high-mass accuracy
measurement of this phosphopeptide in the FTICR cell
(0.9 ppm) and the MS3 spectrum of the precursor ion



















Sequivocal identification of the phosphorylation site (Fig-re 3B). The identified phosphorylation site does not lie
n a perfect RXRXXS/T consensus sequence reported
o be recognized by the anti-RXRXXpS/T motif antibody.
herefore, to determine whether this phosphospecific
ntibody was indeed recognizing DAPK phosphory-
ated at Ser-289, we generated a phosphorylation-defi-
ient mutant of DAPK (Ser289Ala). Mutation of Ser-289
o alanine almost completely inhibited PMA-induced
APK phosphorylation (Figure 3C), indicating that Ser-
89 is the predominant site phosphorylated by the acti-
ation of Ras-MAPK pathway. Thus, the anti-RXRXXpS/
motif antibody appears to recognize similar, but not
dentical, basophilic sequences. We also generated
oint mutations of several other RXRXXS/T sites in
APK, but we did not see any effect on PMA-induced
hosphorylation (data not shown). Moreover, we did not
etect these sites in the MS analysis, notwithstanding
ur conducting of a targeted approach as done for
er-289.
To address the physiological relevance of the RSK-
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1765Figure 3. Ser-289 Is the Major PMA-Regulated Phosphorylation Site in DAPK
(A) HEK293E cells were transfected with Flag-DAPK and treated as shown. A part of the sample was analyzed for DAPK phosphorylation and
ERK1/2 levels. The remainder of the sample was subjected to SDS-PAGE and analyzed by liquid-chromatography tandem MS (LC-MS/MS).
(B) LC-MS/MS/MS identifies phosphorylation of Ser-289 as an in vivo phosphorylation site on DAPK. MS1 analysis (left) was performed in the
FTICR cell, and the base-peak chromatogram for the entire run is shown above an extracted chromatogram for the m/z range from 529.23 to
529.25 encompassing the calculated mass, 529.2419, for the previously observed phosphopeptide, KA(pS)AVNMEK. The observed mass
differed from the calculated mass by less than 1 ppm. Targeted MS2 (center) of the precursor ion and subsequent MS3 (right) of the precursor
ion less the neutral loss of phosphoric acid produced spectra unambiguously identifying the peptide containing phosphorylated serine 289.
(C) HEK293E cells were transfected with either wild-type (WT) or the S289A mutant of DAPK, serum starved, and stimulated with PMA (50
ng/ml) for 15 min. DAPK was immunoprecipitated and immunoblotted for (P)DAPK, DAPK levels, total ERK1/2 levels, and ERK1/2 phosphory-
lation.mediated phosphorylation of DAPK, we determined
whether phosphorylation of DAPK affected its ability to
induce cell death. To test this, we transfected cells with
wild-type or the phosphorylation-deficient DAPK mu-
tant (Ser289Ala) and monitored their ability to induce
cell death by 24 hr. Overexpression of the wild-type
DAPK resulted in about 30% cell death. Interestingly,
mutation of Ser-289 to alanine induced a dramatic in-
crease in proapoptotic activity of DAPK, resulting in en-
hanced cell death (Figure 4A). Cells showed about a
50% enhancement in cell death over the wild-type pro-
tein. By about 48 hr, most of the cells expressing DAPK-
Ser289Ala detached from the substratum. Conversely,
mutation of Ser-289 to glutamic acid reduced the pro-
apoptotic activity of DAPK.
Ser-289 lies in the calmodulin binding domain (Figure
4B). Binding of calcium-activated calmodulin to the cal-
modulin binding domain, during the onset of apoptosis,
has been shown to alter the conformation of DAPK so
that the protein is relieved from autoinhibition [3]. On
the basis of this model, it is possible that phosphoryla-tion of Ser-289 in growing cells may hinder the binding
of calmodulin so that DAPK retains the autoinhibited
conformation. We have not been able to measure sig-
nificant changes in the catalytic activity of the wild-type
or the mutant DAPK proteins when MLC (myosin light
chain) was used as a substrate (data not shown). It is
possible that Ser289Ala mutation may affect the cata-
lytic activity of DAPK toward specific intracellular sub-
strates, and this may play a role in cell death. Contrary
to our findings, a recent report by Chen et al. showed
that activation of ERK in DAPK expressing human
erythroblastic (D2) cells has a proapoptotic rather than
a survival function [23]. These contradictory findings
may be attributed in part to the cell-type differences. In
addition, it is well established that very potent activa-
tion of Ras can lead to cell death [24], although the
molecular basis for this remains unclear. Future work
will undoubtedly reveal how this molecular switch be-
tween survival and death is made by the ERK/RSK/
DAPK protein-kinase module.
Our results support a model wherein activation of
Current Biology
1766Figure 4. Phosphorylation of DAPK on Ser-
289 Antagonizes Its Proapoptotic Activity
(A) Graph showing the relative apoptotic
activities of the vector, WT DAPK, S289A,
and S289E DAPK. HEK293E cells were trans-
fected with the vector, WT DAPK, DAPK
S289A, or DAPK S289E along with the EGFP
plasmid. The apoptotic cells were quantified
as in Figure 1A. All experiments were re-
peated at least three times, and the results
are represented as means ± standard error.
The protein levels of WT DAPK and the mu-
tants are shown.
(B) Schematic representation of the structure
of DAPK, showing various domains and the
PMA-regulated RXRXXS/T site, Ser-289. The
homology alignment showing conservation
of Ser-289 among different mammalian spe-
cies is also shown.Ras-MAPK pathway negatively regulates the cell-death
function of DAPK. In addition to Myt1, DAPK represents
the only other kinase known to be regulated down-
stream of RSK, extending the kinase cascade regulated
by the Ras proto-oncoprotein [25]. DAPK also repre-
sents the second described tumor suppressor, in addi-
tion to TSC2 [15], demonstrated to be antagonized by
activated RSK. When Ras is improperly regulated, as in
30% of human cancers, activation of ERK and RSK, as
well as subsequent inactivation of DAPK and TSC2,
likely contribute to the full tumorigenic phenotype.
Phosphorylation of DAPK by RSK may also be the mech-
anism used to restrain the apoptotic activity of DAPK in
healthy cells. Future studies aimed at resolving the crystal
structure of DAPK along with the regulatory calmodulin
binding domain would provide insight into the role of
regulatory phosphorylation in DAPK function.
Supplemental Data
Supplemental Data include two figures and Experimental Pro-
cedures and are available with this article online at http://www.
current-biology.com/cgi/content/full/15/19/1762/DC1/.
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